Ukr.Biochem.J. 2017; Volume 89, Special Issue, pp. 93-101


Effect of hydrogen sulfide-releasing aspirin on esophageal and gastric mucosa compromised by stress injury

O. S. Zayachkivska1, N. S. Bula1, Ya. I. Pavlovskiy1, I. O. Pshyk-Titko1,
E. M. Gavriluk1, O. I. Grushka1, J. L. Wallace2,3

1Danylo Halytsky Lviv National Medical University, Ukraine;
2University of Calgary, Canada;
3University of Toronto, Canada;

Recent data of study H2S in gastrointestinal tract has proven its potent cytoprotection on mucosal defense among acid-related diseases in the gut. The aim was to evaluate the effects of H2S-releasing aspirin derivative (ATB-340) on esophageal and gastric mucosa compromised by stress injury. Rats were treated with vehicle (control), aspirin (10 mg/kg), ATB-340 (17.5 mg/kg) single or 9 days duration, with or without induction of stress injury. Esophageal mucosa, gastric mucosa were estimated by histopathological damage scoring. Serological levels of VCAM-1, IL-6 by ELISA. ATB-340 treatment resulted in protective effect and lower grade of damage score in esophageal mucosa and gastric mucosa lesions vs effect of aspirin in single or 9 days applications. The serum levels of VCAM, IL-6 in rats who were aspirin-treated and subjected to stress-injury were higher than those in control animals. Treatment with ATB-340 produced an anti-inflammatory effect by decreasing VCAM and IL-6 vs aspirin. Cytoprotective effect of ATB-340 on esophageal mucosa and gastric mucosa was modulated by inhibi­ting inflammation and improving endothelial functions.

Keywords: , , , , , , ,


  1. Kimura H, Shibuya N, Kimura Y. Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxid Redox Signal. 2012 Jul 1;17(1):45-57. Review. PubMed, PubMedCentral, CrossRef
  2. Zaichko NV, Melnik AV, Yoltukhivskyy MM, Olhovskiy AS, Palamarchuk IV. Hydrogen sulfide: metabolism, biological and medical role. Ukr Biochem J. 2014 Sep-Oct;86(5):5-25. Review. PubMed, CrossRef
  3. Chan MV, Wallace JL. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol. 2013 Oct 1;305(7):G467-73. Review. PubMed, CrossRef
  4. Jankowski J, Bennett C, Jankowski JA. Management of Barrett esophagus: a practical guide for clinicians based on the BADCAT and BoB CAT recommendations. Pol Arch Med Wewn. 2015;125(10):765-70. Review. PubMed, CrossRef
  5. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC; Australian Cancer Study. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78. PubMed, CrossRef
  6. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010 Jun;138(7):2260-6. PubMed, PubMedCentral, CrossRef
  7. Peura DA, Wilcox CM. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett’s esophagus. Postgrad Med. 2014 Jan;126(1):87-96. Review. PubMed, CrossRef
  8. Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol. 2011 Jun 7;8(7):385-94. Review. PubMed, CrossRef
  9. Higgs GA, Salmon JA, Henderson B, Vane JR. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci USA. 1987 Mar;84(5):1417-20. PubMed, PubMedCentral, CrossRef
  10. Vane JR. Biomedicine. Back to an aspirin a day? Science. 2002 Apr 19;296(5567):474-5. PubMed, CrossRef
  11. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. PubMed, PubMedCentral, CrossRef
  12. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014 Dec;34(4):771-85. Review. PubMed, PubMedCentral, CrossRef
  13. Blackler RW, Gemici B, Manko A, Wallace JL. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol. 2014 Dec;19:11-6. Review. PubMed, CrossRef
  14. Wallace JL, Blackler RW, Chan MV, Da Silva GJ, Elsheikh W, Flannigan KL, Gamaniek I, Manko A, Wang L, Motta JP, Buret AG. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal. 2015 Feb 10;22(5):398-410.  PubMed,  CrossRef
  15. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski LK, Herndon DN, Wang R, Szabó C. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA. 2009 Dec 22;106(51):21972-7. PubMed, PubMedCentral, CrossRef
  16. Schlesinger M, Bendas G. Vascular cell adhesion molecule-1 (VCAM-1)–an increasing insight into its role in tumorigenicity and metastasis. Int J Cancer. 2015 Jun 1;136(11):2504-14. Review. PubMed, CrossRef
  17. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012 Feb;122(4):143-59. Review. PubMed, CrossRef
  18. Wallace J, Pshyk-Titko I, Marcelo N. Muscara, et al. Influence of Hydrogen Sulfide-releasing aspirin on mucosal integrity of oesophageal and gastric mucosa. Proc Shev Sci Soc.: Med. 2015;XLIII:63-74.
  19. Takagi K, Kasuya Y, Watanabe K. Studies on the drugs for peptic ulcer. A reliable method for producing stress ulcer in rats. Chem Pharm Bull (Tokyo). 1964 Apr;12:465-72. PubMed, CrossRef
  20. Szabo S, Hollander D. Pathways of gastrointestinal protection and repair: mechanisms of action of sucralfate. Am J Med. 1989 Jun 9;86(6A):23-31. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.